The joint venture has resulted in the independent company JAGUAHR Therapeutics, which will focus on developing aryl hydrocarbon receptor antagonists for cancer treatment.
Lenvatinib mesylate was shown to improve overall survival in patients with unresectable liver cancer.
In an attempt to reduce its debt, Valeant will sell its cancer vaccine business to Sanpower Group for US$819.9 million in cash.
These tiny drug- and iron oxide-coated gas bubbles can penetrate deep into cancer cells, with a little help from magnets and ultrasound.
Cortistatin A inhibits cancer tumors from growing blood vessels, but is difficult to harvest from nature. Now, researchers have fully synthesized it in high-yield quantities.
The two companies will conduct clinical trials to assess varlitinib in the treatment of aggressive bile duct cancer, a disease prevalent in South Korea.
Two large scale genomic studies have helped identify strategies for developing more precise and effective treatments for breast cancer.